NCT07543536 2026-04-22
MEGA-TACT-BC3
Sun Yat-sen University
Phase 3 Not yet recruiting
Clinical Trials
12 trialsNCT07060807 2026-04-16
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06324357 2026-04-15
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Phase 1/2 Recruiting
NCT04704661 2026-04-13
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06663787 2026-04-13
HER2 CR
Nagoya City University
Active not recruiting
NCT07137416 2026-04-13
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07198724 2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05950945 2026-04-08
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT05744375 2026-04-02
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT06486883 2026-04-02
PONTIAC
MedSIR
Phase 2 Recruiting
NCT07371585 2026-03-27
TOP-REAL
SOLTI Breast Cancer Research Group
Phase 2 Recruiting
NCT07497386 2026-03-27
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Not yet recruiting